ABSTRACT
1. It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the normal population. 3. There was no tendency for subjects with lung cancer to metabolise debrisoquine more rapidly than non-cancer subjects. 4. It is concluded that debrisoquine metabolic phenotype is not a good predictor of risk of developing lung cancer in the population at large.
Subject(s)
Debrisoquin/metabolism , Isoquinolines/metabolism , Lung Neoplasms/metabolism , Adenocarcinoma/chemically induced , Adenocarcinoma/metabolism , Aged , Aged, 80 and over , Carcinoma, Small Cell/chemically induced , Carcinoma, Small Cell/metabolism , Carcinoma, Squamous Cell/chemically induced , Carcinoma, Squamous Cell/metabolism , Debrisoquin/analogs & derivatives , Debrisoquin/urine , Female , Humans , Lung Neoplasms/chemically induced , Male , Middle Aged , Oxidation-Reduction , Phenotype , Risk , Smoking/metabolismABSTRACT
A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers. The subjects were divided into groups of eight. Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two different tablets. All dosage forms were equivalent to 500 mg of sulfadiazine. Blood samples were obtained at 0, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 25.0, 33.0, and 49.0 hr. Analysis of variance indicated no statistically significant difference (p more than 0.05) between the dosage forms in terms of area under the plasma level--time curve, peak plasma concentration, and time of peak plasma concentration. In both groups, there were differences between products at isolated sampling times. It was concluded that the four tablet formulations of sulfadiazine exhibited bioavailability characteristics equivalent to those of the solution and the suspension.
Subject(s)
Sulfadiazine/metabolism , Administration, Oral , Adult , Biological Availability , Half-Life , Humans , Male , Solutions , Sulfadiazine/administration & dosage , Sulfadiazine/blood , Suspensions , TabletsABSTRACT
The effect of high doses of furosemide, 200 to 800 mg daily, has been studied in 12 Nigerias with edema associated with severe chronic renal failure and hypertension. They all responded well and lost their edema fluid during a period which varied from 10 to 57 days. The fecal water content and the frequency of bowel opening while on furosemide were significantly higher than without furosemide in six of these patients. It is concluded that the gastrointestinal tract is a major contributory site of fluid loss in patients with grossly impaired renal function.
